Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Snap On Incorporated — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Snap On Incorporated trades at $408.11 (market cap $21.30B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Snap On Incorporated pays a 2.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SNA | |
|---|---|---|
Market Cap | $29.60B | $21.30B |
Sector | Health | Technology |
52-Week High | $491.22 | $419.31 |
52-Week Low | $205.48 | $321.38 |
Enterprise Value | $27.56B | $20.93B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Snap-on Incorporated (SNA) trades at $408.44, down 0.65% with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostics capabilities.
SNA offers steady growth potential with strong cash flow generation and consistent dividends, but faces integration risks from recent acquisitions and premium valuation concerns. Analyst consensus remains bullish with $455.33 price target, though execution on growth initiatives will be critical for sustaining momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
